These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 24036641)
1. Adverse event following immunization (AEFI) surveillance in India, position paper of Indian Academy of Pediatrics,2013. Chitkara AJ; Thacker N; Vashishtha VM; Bansal CP; Gupta SG Indian Pediatr; 2013 Aug; 50(8):739-41. PubMed ID: 24036641 [TBL] [Abstract][Full Text] [Related]
2. Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India. Joshi J; Das MK; Polpakara D; Aneja S; Agarwal M; Arora NK Indian J Pediatr; 2018 Feb; 85(2):139-148. PubMed ID: 29170922 [TBL] [Abstract][Full Text] [Related]
3. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015. Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723 [TBL] [Abstract][Full Text] [Related]
4. Causality assessment of serious and severe adverse events following immunization in India: a 4-year practical experience. Singh AK; Wagner AL; Joshi J; Carlson BF; Aneja S; Boulton ML Expert Rev Vaccines; 2018 Jun; 17(6):555-562. PubMed ID: 29865876 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia. Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074 [TBL] [Abstract][Full Text] [Related]
6. Surveillance of adverse events following immunisation in Australia annual report, 2017. Dey A; Wang H; Quinn H; Hiam R; Wood N; Beard F; Macartney K Commun Dis Intell (2018); 2019 Jul; 43():. PubMed ID: 31315166 [TBL] [Abstract][Full Text] [Related]
7. Annual report: Surveillance of adverse events following immunisation in Australia, 2005. Lawrence G; Boyd I; McIntyre P; Isaacs D Commun Dis Intell Q Rep; 2006; 30(3):319-33. PubMed ID: 17120485 [TBL] [Abstract][Full Text] [Related]
8. [Surveillance of adverse events following immunization in Minhang district of Shanghai from 2007 to 2010]. Zhang LP; Yu F; Jin BF; Wang Y; Xu HL; DU Y Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):859-64. PubMed ID: 23302620 [TBL] [Abstract][Full Text] [Related]
9. Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign. Gbenewei E; Nomhwange T; Taiwo L; Ayodeji I; Yusuf K; Jean Baptiste AE; Nsubuga P; Braka F; Oteri J; Shuaib F Vaccine; 2021 Nov; 39 Suppl 3():C82-C88. PubMed ID: 33714655 [TBL] [Abstract][Full Text] [Related]
10. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015. Lei J; Balakrishnan MR; Gidudu JF; Zuber PLF Vaccine; 2018 Mar; 36(12):1577-1582. PubMed ID: 29454518 [TBL] [Abstract][Full Text] [Related]
11. Surveillance of adverse events following immunisation: Australia 2002 to 2003. Lawrence G; Boyd I; McIntyre P; Isaacs D Commun Dis Intell Q Rep; 2004; 28(3):324-38. PubMed ID: 15574056 [TBL] [Abstract][Full Text] [Related]
12. Improving AEFI surveillance in India. Mahajan V; Saini SS Indian Pediatr; 2014 Mar; 51(3):233. PubMed ID: 24736920 [No Abstract] [Full Text] [Related]
13. Annual report on surveillance of adverse events following immunisation in Australia, 2006. Lawrence GL; Aratchige PE; Boyd I; McIntyre PB; Gold MS Commun Dis Intell Q Rep; 2007 Sep; 31(3):269-82. PubMed ID: 17974219 [TBL] [Abstract][Full Text] [Related]
14. Adverse events following immunization in Ontario's female school-based HPV program. Harris T; Williams DM; Fediurek J; Scott T; Deeks SL Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208 [TBL] [Abstract][Full Text] [Related]
15. Annual report: Surveillance of adverse events following immunisation in Australia, 2011. Mahajan D; Cook J; Dey A; Macartney K; Menzies RI Commun Dis Intell Q Rep; 2012 Dec; 36(4):E315-32. PubMed ID: 23330706 [TBL] [Abstract][Full Text] [Related]
16. Vaccine pharmacovigilance in India: Current context and future perspective. Meher BR Indian J Pharmacol; 2019; 51(4):243-247. PubMed ID: 31571710 [TBL] [Abstract][Full Text] [Related]
17. Annual report: surveillance of adverse events following immunisation in Australia, 2004. Lawrence GL; Boyd I; McIntyre PB; Isaacs D Commun Dis Intell Q Rep; 2005; 29(3):248-62. PubMed ID: 16220860 [TBL] [Abstract][Full Text] [Related]
18. Analysis of death cases in Shenyang City, China, for immunization adverse event surveillance, 2009-2021. Gao D; Dong G; Zhu L; Jia N; Sun B Hum Vaccin Immunother; 2023 Aug; 19(2):2263225. PubMed ID: 37782096 [TBL] [Abstract][Full Text] [Related]
19. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Lawrence G; Gold MS; Hill R; Deeks S; Glasswell A; McIntyre PB Commun Dis Intell Q Rep; 2008 Dec; 32(4):371-87. PubMed ID: 19374268 [TBL] [Abstract][Full Text] [Related]
20. Surveillance of adverse events following immunisation: Australia, 2000-2002. Lawrence G; Menzies R; Burgess M; McIntyre P; Wood N; Boyd I; Purcell P; Isaacs D Commun Dis Intell Q Rep; 2003; 27(3):307-23. PubMed ID: 14510057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]